ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,51
0,35%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08722
-0,02%
Bitcoin
67.215,44
1,59%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. NovoCure Ltd (NVCR)

  7. NovoCure Ltd (NVCR) News

NVCR

NovoCure (NVCR)

NovoCure Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NVCR
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202413h01Business WireNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from PharmakonNASDAQ:NVCRNovoCure Ltd
02/05/202413h00Business WireNovocure Reports First Quarter 2024 Financial ResultsNASDAQ:NVCRNovoCure Ltd
24/04/202416h45Business WireResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024NASDAQ:NVCRNovoCure Ltd
05/04/202413h00Business WireNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:NVCRNovoCure Ltd
01/04/202413h00Business WireNovocure to Report First Quarter 2024 Financial ResultsNASDAQ:NVCRNovoCure Ltd
29/03/202401h07Business WireMETIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長NASDAQ:NVCRNovoCure Ltd
28/03/202418h51Business WireKlinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem LungenkrebsNASDAQ:NVCRNovoCure Ltd
28/03/202418h50Business WireL’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives..NASDAQ:NVCRNovoCure Ltd
27/03/202412h00Business WireMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerNASDAQ:NVCRNovoCure Ltd
11/03/202412h00Business WireINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGONASDAQ:NVCRNovoCure Ltd
05/03/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
05/03/202400h39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
04/03/202423h56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
01/03/202423h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
01/03/202423h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NVCRNovoCure Ltd
29/02/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
29/02/202422h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
29/02/202422h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
29/02/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
29/02/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
22/02/202413h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NVCRNovoCure Ltd
22/02/202413h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVCRNovoCure Ltd
22/02/202413h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NVCRNovoCure Ltd
22/02/202413h00Business WireNovocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateNASDAQ:NVCRNovoCure Ltd
18/01/202417h10Dow Jones NewsNovocure Shares Rise 17% After FDA Accepts Pre-Market ApplicationNASDAQ:NVCRNovoCure Ltd
18/01/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVCRNovoCure Ltd
18/01/202413h00Business WireNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung CancerNASDAQ:NVCRNovoCure Ltd
12/01/202422h57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
11/01/202423h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NVCRNovoCure Ltd
09/01/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVCRNovoCure Ltd
 Showing the most relevant articles for your search:NASDAQ:NVCR

Kürzlich von Ihnen besucht

TG
UL9
Azimut Exploration
TG
829
AppHarvest
TG
1D8
Accsys Technologies
TG
27W
PowerCell Sweden AB
USOTC
THBD
Third Bench (PK)
AMEX
RJMG
FT Raymond James Multica...
USOTC
ASRMF
Grupo Aeroportuario Del ... (PK)
TG
L9O
Labrador Iron Ore Royalty
COIN
EPSSUST
Epanus
COIN
ENKEUR
TG
7RZ
Augusta Gold
TG
AGL
Agree Realty
USOTC
BXRBF
Bendigo and Adelaide Bank (PK)
NASDAQ
FAFVVX
Defensive Equity Portfol...
AMEX
BBHY
JPMorgan BetaBuilders US...
AMEX
IBMM
iShares iBonds Dec 2024 ...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten